The FDA will no longer require the label of Johnson &
Johnson's diabetes drug Invokana to bear a boxed warning about increased risk
of foot and leg amputations. The decision was based on clinical trial data
suggesting that the risk of amputation, though still increased with Invokana,
is lower than previously reported with proper monitoring.
No comments:
Post a Comment